Shares of Plus Therapeutics, Inc. PSTV were up a staggering 170.1% on March 20 after the company announced that the FDA has conditionally accepted — Reyobiq — as the new proprietary name for PSTV’s ...
HOUSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced ...
Plus Therapeutics (PSTV) announces the U.S. Food and Drug Administration, FDA, has conditionally accepted the Company’s new proprietary name, REYOBIQ, for its lead therapeutic candidate. A request for ...
- Xyngari (formerly DMT310) is currently being studied in Phase 3 for the treatment of acne, with topline results from the first Phase 3 STAR-1 study expected in March 2025 - SAN DIEGO, CA / ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback